Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates
Portfolio Pulse from
Voyager Therapeutics (VYGR) reported a Q4 loss of $0.59 per share, missing the Zacks Consensus Estimate of a $0.35 loss. This is a significant decline from the $1.25 earnings per share reported a year ago.
March 11, 2025 | 10:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Voyager Therapeutics reported a larger-than-expected Q4 loss of $0.59 per share, missing the consensus estimate of a $0.35 loss. This marks a significant decline from the previous year's earnings of $1.25 per share.
The reported loss per share was significantly higher than the consensus estimate, indicating worse-than-expected financial performance. This is likely to negatively impact the stock price in the short term as investors react to the earnings miss.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100